Insider Buying: Biomerica (NASDAQ:BMRA) Vice Chairman Acquires $32,000.00 in Stock

Biomerica, Inc. (NASDAQ:BMRA) Vice Chairman Allen Barbieri acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were purchased at an average price of $1.60 per share, with a total value of $32,000.00. Following the completion of the transaction, the insider owned 73,542 shares of the company’s stock, valued at $117,667.20. The trade was a 37.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Biomerica Price Performance

Shares of NASDAQ BMRA opened at $2.14 on Friday. Biomerica, Inc. has a 1 year low of $1.45 and a 1 year high of $3.22. The company has a market capitalization of $6.61 million, a P/E ratio of -2.40 and a beta of 0.35. The company has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $1.99.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Biomerica stock. BlackRock Inc. acquired a new position in shares of Biomerica, Inc. (NASDAQ:BMRA) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 18,636 shares of the company’s stock, valued at approximately $33,000. BlackRock Inc. owned approximately 0.60% of Biomerica as of its most recent filing with the Securities & Exchange Commission. 22.28% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BMRA shares. Weiss Ratings lowered shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, June 5th. Citizens Jmp assumed coverage on Biomerica in a research report on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 target price on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell” and a consensus price target of $9.00.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.